Selective radiosensitization of p53 mutant pancreatic cancer cells by combined inhibition of Chk1 and PARP1

Evaluation of an Actinomycin D/VX-680 aurora kinase inhibitor combination in p53-based cyclotherapy

(2015)   Oncotarget

Pharmacological manipulation of the cell cycle and metabolism to protect normal tissues against conventional anticancer drugs

(2015) Ingeborg van Leeuwen et al.   Oncotarget

Exploring long-term protection of normal human fibroblasts and epithelial cells from chemotherapy in cell culture

(2015) Pasha Apontes et al.   Oncotarget

Radiotherapy Combined with Gemcitabine and Oxaliplatin in Pancreatic Cancer Cells

(2014) Meredith A. Morgan et al.   Translational Oncology

Chk1 inhibition after replicative stress activates a double strand break response mediated by ATM and DNA-dependent protein kinase

(2011) Samuel McNeely et al.   CELL CYCLE

Assessment of Chk1 Phosphorylation as a Pharmacodynamic Biomarker of Chk1 Inhibition

(2011) L. A. Parsels et al.   CLINICAL CANCER RESEARCH

Combining ATR Suppression with Oncogenic Ras Synergistically Increases Genomic Instability, Causing Synthetic Lethality or Tumorigenesis in a Dosage-Dependent Manner

(2010) O. Gilad et al.   CANCER RESEARCH

Mechanism of Radiosensitization by the Chk1/2 Inhibitor AZD7762 Involves Abrogation of the G2Checkpoint and Inhibition of Homologous Recombinational DNA Repair

(2010) Meredith A. Morgan et al.   CANCER RESEARCH

Radiosensitization by Chir-124, a selective Chk1 inhibitor: Effects of p53 and cell cycle checkpoints

(2010) Yungan Tao et al.   CELL CYCLE

In vitro and In vivo Radiation Sensitization of Human Tumor Cells by a Novel Checkpoint Kinase Inhibitor, AZD7762

(2010) J. B. Mitchell et al.   CLINICAL CANCER RESEARCH

Histone  H2AX and Poly(ADP-Ribose) as Clinical Pharmacodynamic Biomarkers

(2010) C. E. Redon et al.   CLINICAL CANCER RESEARCH

The Preclinical Pharmacology and Therapeutic Activity of the Novel CHK1 Inhibitor SAR-020106

(2010) M. I. Walton et al.   MOLECULAR CANCER THERAPEUTICS

Context-Dependent Cell Cycle Checkpoint Abrogation by a Novel Kinase Inhibitor

(2010) Andrew J. Massey et al.   PLoS One

Poly(ADP-Ribose) Polymerase Inhibition as a Model for Synthetic Lethality in Developing Radiation Oncology Targets

(2010) Anthony J. Chalmers et al.   SEMINARS IN RADIATION ONCOLOGY

Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics

(2010) Cynthia X. Ma et al.   TRENDS IN MOLECULAR MEDICINE

In vitro and In vivo Radiosensitization of Glioblastoma Cells by the Poly (ADP-Ribose) Polymerase Inhibitor E7016

(2009) A. L. Russo et al.   CLINICAL CANCER RESEARCH

Using a Bigger Hammer: The Role of Stereotactic Body Radiotherapy in the Management of Oligometastases

(2009) Edgar Ben-Josef et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase 0 Clinical Trial of the Poly (ADP-Ribose) Polymerase Inhibitor ABT-888 in Patients With Advanced Malignancies

(2009) Shivaani Kummar et al.   JOURNAL OF CLINICAL ONCOLOGY

DPC4 Gene Status of the Primary Carcinoma Correlates With Patterns of Failure in Patients With Pancreatic Cancer

(2009) Christine A. Iacobuzio-Donahue et al.   JOURNAL OF CLINICAL ONCOLOGY

Enhanced radiosensitization of human glioma cells by combining inhibition of poly(ADP-ribose) polymerase with inhibition of heat shock protein 90

(2009) F. A. Dungey et al.   MOLECULAR CANCER THERAPEUTICS

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers

(2009) Peter C. Fong et al.   NEW ENGLAND JOURNAL OF MEDICINE

Checkpoint Kinase 1 Down-Regulation by an Inducible Small Interfering RNA Expression System Sensitized In vivo Tumors to Treatment with 5-Fluorouracil

(2008) M. Ganzinelli et al.   CLINICAL CANCER RESEARCH

The Combination of Epidermal Growth Factor Receptor Inhibitors with Gemcitabine and Radiation in Pancreatic Cancer

(2008) M. A. Morgan et al.   CLINICAL CANCER RESEARCH

Replication-Dependent Radiosensitization of Human Glioma Cells by Inhibition of Poly(ADP-Ribose) Polymerase: Mechanisms and Therapeutic Potential

(2008) Fiona A. Dungey et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Defective p53 signaling in p53 wild-type tumors attenuates p21waf1 induction and cyclin B repression rendering them sensitive to Chk1 inhibitors that abrogate DNA damage-induced S and G2 arrest

(2008) A. A. Levesque et al.   MOLECULAR CANCER THERAPEUTICS

Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1

(2008) A. Blasina et al.   MOLECULAR CANCER THERAPEUTICS

AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies

(2008) S. D. Zabludoff et al.   MOLECULAR CANCER THERAPEUTICS